NCT04666649View on ClinicalTrials.gov

Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

March 10, 2021

Primary Completion Date

September 1, 2024

Study Completion Date

May 23, 2025

Conditions
Relapsed or Refractory Acute Myeloid Leukemia
Interventions
DRUG

Venetoclax and pegcrisantaspase

Therapeutic

Trial Locations (1)

21201

Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore

All Listed Sponsors
lead

University of Maryland, Baltimore

OTHER

NCT04666649 - Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) | Biotech Hunter | Biotech Hunter